Aldeyra Therapeutics, Inc. (ALDX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aldeyra Therapeutics, Inc. (ALDX) Healthcare & Pipeline Overview

Aldeyra Therapeutics, Inc. is a biotechnology firm specializing in innovative therapies for immune-mediated diseases, particularly ocular conditions. Their lead candidate, reproxalap, a RASP modulator, is in late-stage clinical trials targeting significant unmet needs in dry eye disease and allergic conjunctivitis, positioning them for potential market entry.

What Is the Investment Thesis for ALDX?

Aldeyra Therapeutics presents a notable research candidate based on its innovative RASP modulation technology and promising clinical pipeline. The primary value driver is the potential approval and commercialization of reproxalap for dry eye disease and allergic conjunctivitis, addressing a significant market with limited effective treatments. Positive Phase III trial results and subsequent FDA approval could lead to substantial revenue growth. Furthermore, the advancement of ADX-629 and ADX-2191 in other immune-mediated diseases offers additional upside potential. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from established pharmaceutical companies. Successful execution of clinical programs and effective commercialization strategies are crucial for realizing the company's full potential. With a market capitalization of $89.0M, Aldeyra offers a high-risk, high-reward investment profile.

Based on FMP financials and quantitative analysis

ALDX Key Highlights

Reproxalap, Aldeyra's lead product candidate, is in Phase III clinical trials for dry eye disease and allergic conjunctivitis, targeting a large patient population.

• ADX-629, an orally administered RASP modulator, is in Phase II clinical trials for psoriasis, asthma, and COVID-19, expanding the potential therapeutic applications of Aldeyra's technology.
• ADX-2191, a dihydrofolate reductase inhibitor, is in Phase III for proliferative vitreoretinopathy and Phase II for retinitis pigmentosa and primary vitreoretinal lymphoma, addressing niche but significant ophthalmic indications.
• Aldeyra has a license agreement with Madrigal Pharmaceuticals, Inc. for ADX-1612, indicating potential partnerships and external validation of their technology.
• The company's focus on RASP modulation represents a novel approach to treating immune-mediated diseases, potentially offering advantages over existing therapies.

Who Are ALDX's Competitors?

ALDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALDX's Key Strengths?

Novel RASP modulation technology.

• Advanced clinical pipeline.
• Experienced management team.
• Strong intellectual property protection.

What Are ALDX's Weaknesses?

Small company size.

• Limited financial resources.
• Dependence on clinical trial outcomes.
• Competition from larger pharmaceutical companies.

What Could Drive ALDX Stock Higher?

Reproxalap Phase III clinical trial results for dry eye disease.

• Reproxalap Phase III clinical trial results for allergic conjunctivitis.
• ADX-629 Phase II clinical trial results for psoriasis.
• ADX-629 Phase II clinical trial results for asthma.
• ADX-2191 Phase III clinical trial results for proliferative vitreoretinopathy.

What Are the Key Risks for ALDX?

Financial-distress signal — its Altman Z-Score of -9.44 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-0.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for reproxalap or other drug candidates.
• Regulatory setbacks or delays in obtaining FDA approval.
• Competition from existing therapies for dry eye disease and other indications.
• Patent challenges or intellectual property disputes.
• Dependence on external funding and capital markets.

What Are the Growth Opportunities for ALDX?

• Growth opportunity 1: Reproxalap's approval and commercialization for dry eye disease represents a significant growth opportunity. Successful Phase III trial results and subsequent FDA approval could drive rapid revenue growth for Aldeyra. The timeline for potential approval is dependent on clinical trial outcomes and regulatory review, but could occur within the next 1-2 years. Aldeyra's competitive advantage lies in reproxalap's novel mechanism of action as a RASP modulator.
• Growth opportunity 2: Expansion of ADX-629 into additional indications beyond psoriasis, asthma, and COVID-19 offers further growth potential. The oral RASP modulator could have broad applications in various immune-mediated diseases. Positive Phase II trial results in these initial indications could pave the way for further clinical development and commercialization. The timeline for expansion into new indications is dependent on clinical trial progress and regulatory strategy. Aldeyra's expertise in RASP modulation provides a competitive advantage in this area.
• Growth opportunity 3: Advancement of ADX-2191 in proliferative vitreoretinopathy (PVR) and retinitis pigmentosa represents another growth opportunity. These are niche ophthalmic indications with limited treatment options. Successful Phase III trial results in PVR and Phase II results in retinitis pigmentosa could lead to regulatory approvals and commercialization. The timeline for potential approval is dependent on clinical trial outcomes and regulatory review. Aldeyra's focus on these underserved indications provides a competitive advantage.
• Growth opportunity 4: Potential partnerships and collaborations with larger pharmaceutical companies could accelerate the development and commercialization of Aldeyra's pipeline. The license agreement with Madrigal Pharmaceuticals for ADX-1612 demonstrates the potential for such collaborations. Strategic partnerships could provide access to resources, expertise, and market reach. The timeline for future partnerships is uncertain, but could occur as Aldeyra's pipeline advances and its technology gains further validation. This would enhance Aldeyra's competitive position.
• Growth opportunity 5: Geographic expansion beyond the United States represents a long-term growth opportunity. The global market for immune-mediated disease therapies is substantial. Obtaining regulatory approvals in other countries and establishing commercial operations could drive revenue growth. The timeline for geographic expansion is dependent on regulatory strategy and market conditions. Aldeyra's innovative technology and promising clinical pipeline could attract international interest and support expansion efforts.

What Are ALDX's Competitive Advantages?

• Proprietary RASP modulation technology.
• Strong intellectual property protection for their drug candidates.
• Advanced clinical pipeline with multiple Phase II and Phase III trials.
• Experienced management team with expertise in drug development and commercialization.

What Does ALDX Do?

Aldeyra Therapeutics, Inc., founded in 2004 and based in Lexington, Massachusetts, is a biotechnology company dedicated to developing and commercializing novel therapies for immune-mediated ocular and systemic diseases. The company's core focus is on reactive aldehyde species (RASP) modulation, a unique approach to addressing inflammation and immune dysfunction. Their lead product candidate, reproxalap, is a RASP modulator currently in Phase III clinical trials for the treatment of dry eye disease and allergic conjunctivitis, two prevalent and underserved conditions. Beyond reproxalap, Aldeyra is advancing a pipeline of innovative therapies, including ADX-629, an orally administered RASP modulator in Phase II clinical trials for psoriasis, asthma, and COVID-19, and ADX-2191, a dihydrofolate reductase inhibitor in Phase III for proliferative vitreoretinopathy and Phase II for retinitis pigmentosa and primary vitreoretinal lymphoma. Aldeyra also has a license agreement with Madrigal Pharmaceuticals, Inc. for ADX-1612, targeting inflammatory diseases. Formerly known as Aldexa Therapeutics, Inc., the company rebranded in 2014 to reflect its evolving focus on aldehyde modulation. With a small but dedicated team of 9 employees, Aldeyra is striving to bring innovative solutions to patients suffering from immune-mediated diseases.

What Products and Services Does ALDX Offer?

• Develop and commercialize medicines for immune-mediated ocular diseases.
• Develop and commercialize medicines for immune-mediated systemic diseases.
• Focus on reactive aldehyde species (RASP) modulation.
• Conduct Phase III clinical trials for reproxalap in dry eye disease.
• Conduct Phase III clinical trials for reproxalap in allergic conjunctivitis.
• Develop ADX-629, an orally administered RASP modulator.
• Develop ADX-2191, a dihydrofolate reductase inhibitor.

How Does ALDX Make Money?

• Develop novel therapies for immune-mediated diseases.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Seek regulatory approvals from the FDA and other regulatory agencies.
• Commercialize approved products through their own sales force or through partnerships.

What Industry Does ALDX Operate In?

Aldeyra Therapeutics operates within the biotechnology industry, specifically targeting the immune-mediated disease market. This sector is characterized by high growth potential, driven by an aging population and increasing prevalence of chronic diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms developing innovative therapies. Aldeyra's focus on RASP modulation differentiates it from competitors, offering a unique mechanism of action. The dry eye disease market, in particular, is expected to grow significantly, driven by increased awareness and unmet needs. Success in this market could position Aldeyra as a key player in the ophthalmology space.

Who Are ALDX's Key Customers?

• Patients suffering from dry eye disease.
• Patients suffering from allergic conjunctivitis.
• Patients suffering from psoriasis.
• Patients suffering from asthma.
• Patients suffering from COVID-19.
• Patients suffering from proliferative vitreoretinopathy.
• Patients suffering from retinitis pigmentosa.
• Patients suffering from primary vitreoretinal lymphoma.

Aldeyra Therapeutics, Inc. Financial Trajectory

Aldeyra Therapeutics, Inc. (ALDX) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $5.5M, with diluted EPS of $-0.09. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ALDX averaged $-0.10 in diluted EPS.

Company Profile

Aldeyra Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lexington, US. The company is led by CEO Todd C. Brady. ALDX has traded publicly since 2014.

How Aldeyra Therapeutics, Inc. Is Valued

Aldeyra Therapeutics, Inc. carries a market capitalization of $89.0M, placing it in the micro-cap category. Analyst price targets span from $7.00 to $12.00, with a consensus of $9.67. At the current price of $1.48, that implies approximately 556% upside potential. Relative to its peer group, ALDX's quantitative score of 30/100 is below the peer average of 81/100.

Return on equity for Aldeyra Therapeutics, Inc. stands at -0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -26.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.72 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -28.0%, the inverse of the P/E and a quick read on earnings relative to price.

Aldeyra Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.44 places it in the distress zone, a signal of elevated financial risk.

Aldeyra Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 18.0% above estimates on average.

Over the past six months, Aldeyra Therapeutics, Inc. insiders filed 22 SEC Form 4 transactions — 0 sales and 22 purchases. On net that is roughly 3.4M shares acquired (about $4.8M) — insiders putting money in tends to read as conviction.

ALDX Financials

ALDX Latest News

ALDX Analyst Consensus

ALDX MoonshotScore

Latest Aldeyra Therapeutics, Inc. Analysis

Aldeyra Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources